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Introduction: PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α) somatic mutations are the
most common genetic alteration in breast cancer (BC). Their prognostic value and that of the phosphatidylinositol
3-kinase (PI3K) pathway in BC remains only partly defined. The effect of PIK3CA mutations and alterations of the
PI3K pathway on the antiproliferative response to aromatase inhibitor treatment was determined.
Methods: The Sequenom MassARRAY System was used to determine the presence of 20 somatic mutations
across the PIK3CA gene in 85 oestrogen receptor–positive (ER+) BC patients treated with 2 weeks of anastrozole
before surgery. Whole-genome expression profiles were used to interrogate gene signatures (GSs) associated
with the PI3K pathway. Antiproliferative activity was assessed by the change in Ki67 staining between baseline
and surgery. Three GSs representing the PI3K pathway were assessed (PIK3CA-GS (Loi), PI3K-GS (Creighton) and
PTEN-loss-GS (Saal)).
Results: In our study sample, 29% of tumours presented with either a hotspot (HS, 71%) or a nonhotspot (non-HS, 29%)
PIK3CA mutation. Mutations were associated with markers of good prognosis such as progesterone receptor positivity
(PgR+) (P = 0.006), low grade (P = 0.028) and luminal A subtype (P = 0.039), with a trend towards significance with
degree of ER positivity (P = 0.051) and low levels of Ki67 (P = 0.051). Non-HS mutations were associated with higher
PgR (P = 0.014) and ER (P < 0.001) expression than both wild-type (WT) and HS-mutated samples, whereas neither
biomarker differed significantly between WT and HS mutations or between HS and non-HS mutations. An inverse
correlation was found between the Loi signature and both the Creighton and Saal signatures, and a positive correlation
was found between the latter signatures. Lower pretreatment Ki67 levels were observed in mutation compared with WT
samples (P = 0.051), which was confirmed in an independent data set. Mutation status did not predict change in Ki67 in
response to 2 weeks of anastrozole treatment; there was no significant difference between HS and non-HS mutations in
this regard.
Conclusions: PIK3CA mutations are associated with classical markers of good prognosis and signatures of PI3K pathway
activity. The presence of a PIK3CA mutation does not preclude a response to neoadjuvant anastrozole treatment.* Correspondence: elena.lopez-knowles@icr.ac.uk
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About 80% of primary breast cancer (BC) presents as
oestrogen receptor–positive (ER+) disease [1]. In post-
menopausal patients, aromatase inhibition is the most
effective means of treatment, reducing the relative risk
of recurrence by 20% to 25% from the results achieved
with tamoxifen therapy. However, resistance remains a
substantial problem and is the focus for the development
of new therapeutic strategies targeting putative resist-
ance mechanisms.
To date, although researchers in in vitro studies have
reported large numbers of putative mechanisms of re-
sistance, few of these mechanisms have been confirmed
as clinically relevant (for example, loss of ER expression,
de novo or acquired overexpression of human epidermal
growth factor receptor 2 (HER2)) [2]. Detailed molecular
characterisation of individual tumours, along with assess-
ment of clinical efficacy, is required in order to identify
additional mechanisms and determine their importance.
This is particularly relevant, given that multiple new agents
with targets that have putative involvement in endocrine
resistance are now available [3].
The phosphatidylinositol 3-kinase (PI3K) pathway is
frequently altered in cancer and is a focus of interest in
ER + BC. This pathway links the signalling of type I and
type II receptor tyrosine kinases (epidermal growth
factor (EGFR), HER2 and insulin-like growth factor 1
receptor) to the effector serine/threonine kinase moiety
AKT. Complete phosphorylation of AKT results in acti-
vation of the mammalian target of rapamycin (mTOR)/
regulated associated protein of TOR (Raptor) complex 1
(mTORC1), which regulates cell proliferation and pro-
tein synthesis [3]. The phosphatase and tensin homo-
log (PTEN) tumour suppressor gene, amongst others, is a
negative regulator of the PI3K pathway and is often lost in
BC [4], leading to enhanced activation of AKT and down-
stream partners.
Whilst there are multiple isoforms of the PI3K regula-
tory and catalytic subunits, single amino acid substitu-
tions in BC are frequently found in the catalytic subunit
p110α (PIK3CA), in which the occurrence of mutations
is reported to be between 18% and 41% [4-15]. Within
PIK3CA, there are three major hotspots (HSs) of muta-
tions concentrated in the helical (E542K and E545K) and
kinase (H1047R) domains, accounting for approximately
89% of PIK3CA mutations [13].
PIK3CA mutations have been reported to be asso-
ciated with markers of good prognosis, such as high
ER, high PgR, smaller size, earlier stage, lower grade
[5-7,13,14] and better outcome in ER+/HER2− disease,
as well as with good prognosis with tamoxifen mono-
therapy, relapse-free survival, overall survival and BC-
specific survival [5,6,16]. In contrast, BC patients with
PIK3CA mutations and HER2 amplification have beenfound to exhibit significantly shorter progression-free
survival following trastuzumab-based treatment [17].
However, in some cases, study researchers who have re-
ported conflicting results have been unable to verify these
associations [10,13,16].
Recognition of the frequency of PIK3CA mutations in
clinical specimens and their oncogenic nature in vitro
has led to the clinical development of numerous inhibi-
tors of the pathway. The appropriate targeting of these
agents in postmenopausal patients with ER + disease re-
quires an improved understanding of the importance of
PIK3CA mutations and PI3K pathway activation to BC
response or resistance to aromatase inhibition. This insight
should have a significant impact on the design and inter-
pretation of clinical trials of endocrine therapy with PI3K
pathway–targeted inhibitors.
Study of the influence of putative mechanisms and
markers of resistance in early disease is not possible at
an individual patient level in relation to benefit from ad-
juvant therapy, owing to the absence of reliable markers
of subclinical disease and the inability to characterise the
molecular nature of micrometastatic disease. In contrast,
presurgical treatment allows the response of primary dis-
ease (unaffected by previous therapy) to be characterised
by multiple means and to be correlated with the mo-
lecular characteristics. The nuclear proliferation marker
Ki67 has been validated as an intermediate endpoint of
evaluation of benefit from endocrine therapy in mul-
tiple studies, and it is therefore helpful for studying both
resistance and the impact of targeted therapies alongside
endocrine agents [18].
We therefore conducted a comprehensive assessment
of PIK3CA mutation status and gene signatures (GSs) of
PI3K pathway activity in tumours from patients with
ER + primary BC in a clinical trial of the aromatase in-
hibitor anastrozole and related these to the drug’s anti-
proliferative effects and other key biomarkers of prognosis
in ER + disease.
Methods
Tissue specimens
All available pretreatment (baseline) core-cut tumour
samples were selected for analysis from patients who
received the aromatase inhibitor anastrozole alone prior
to biopsy in the multicentre 0223 neoadjuvant study
(ZD1839IL/0223) of anastrozole with or without EGFR
inhibitor gefitinib in ER + primary BC [19]. The original
study received approval from an institutional review
board at each site and was conducted in accordance with
the 1964 Declaration of Helsinki and the International
Conference on Harmonization/Good Clinical Practice
guidelines. Written informed consent was obtained from
each patient before participation. Tumour size was mea-
sured by caliper, magnetic resonance imaging, physical
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centre. Previously reported scores for ER, PgR, HER2
(positivity (+) or negativity (−) by immunohistochemistry
(IHC) and fluorescence in situ hybridisation) and Ki67
levels (percentage of positive cells) were available [19].
ER and PgR expression were assessed by H-score, which
incorporates both the staining intensity (scored from
0 to 3) and the percentage of cells stained. For both
biomarkers, we used an H-score ≥1 as a cut-off for des-
ignation of positive or negative status in accordance
with the American Society of Clinical Oncology/College
of American Pathologists guidelines for ER and PgR
positivity [20].
Percent residual Ki67 was defined as (2-week Ki67
level ÷ baseline Ki67 level) × 100. This percentage was
used as an endpoint for treatment response, both as a
continuous variable and dichotomised into responders
or nonresponders according to a 2-week/pre-Ki67 re-
sidual <65% or > 65%, respectively [19]. This cut-off was
a prospectively defined primary endpoint of the original
study and has previously been shown to predict clinical
response to hormone therapy.
Validation data set
Tumours from a set of 310 pretreatment ER + patients,
predominantly HER2−, from 2 neoadjuvant aromatase
inhibitor studies were used for confirmation of the rela-
tionship of Ki67 data with PIK3CA mutation status [9].
Gene expression arrays
Whole-genome expression data for 66 pretreatment bi-
opsies and their derivation have been described in detail
previously [21]. Intrinsic subtyping was assigned using
the 50-gene predictor for luminal A and luminal B sub-
types together with the gene expression data [22].
PIK3CA mutation analysis
Multiple (one to three) 10-μm sections were taken from
formalin-fixed, paraffin-embedded material, stained with
nuclear fast red and needle-dissected for tumour-enriched
areas using adjacent haematoxylin and eosin–stained sec-
tions as a guide, with the aim of yielding >70% malignant
tissue. DNA was extracted using the DNeasy Tissue &
Blood Kit (Qiagen, Hilden, Germany) with xylene and
ethanol washes to remove paraffin and an overnight
incubation in 1 M NaSCN. Nonsynonymous somatic
PIK3CA mutations previously described in BC patients
were selected from public databases, including COSMIC
[23] and the National Cancer Institute’s somatic mutation
database [24]. Mutation detection was conducted by
using the Sequenom MassARRAY System (Sequenom,
San Diego, CA, USA) as described by others [25]. In
brief, with this array, DNA is amplified and treated with
shrimp alkaline phosphatase to neutralise unincorporateddeoxyribonucleotide triphosphates, the mutation site
is extended and the sample is read by matrix-assisted
laser desorption/ionisation time-of-flight (MALDI-TOF)
mass spectrometry analysis. PCR and extension primers
were designed using Sequenom Assay Design Software
(Sequenom) and covered 20 mutations (3 HS and 17 low-
frequency mutations) using 5 multiplexes (Additional
file 1: Table S1). To be considered mutated, the proportion
of the mutant allele had to be ≥10% as calculated by the
allelotyping function of the Sequenom system.
Droplet digital PCR
HS mutations identified by mass spectrometry–based
genotyping were confirmed using a droplet digital PCR
(ddPCR) system (Bio-Rad Laboratories, Hercules, CA,
USA). Digital PCRs were performed using this system
with PIK3CA primers and probes (described in Additional
file 2: Table S2) at final concentrations of 900 nM for
primers and 250 nM for probes.
PCRs were prepared with 10 μl of master mix in a total
volume of 20 μl and partitioned into approximately 14,000
droplets per sample in the droplet generator component
of the QX100 ddPCR system according to the manufac-
turer’s instructions. Emulsified PCRs were run on a
96-well plate on a G-Storm GS4 thermal cycler (G-Storm,
Somerton, UK). The plates were incubated at 95°C for
10 minutes, followed by 45 cycles at 95°C for 15 seconds
and 63.1°C for 60 seconds (exon 9), or 45 cycles at 95°C
for 15 seconds and 61.7°C for 60 seconds (exon 20), and
then by a 10-minute incubation at 98°C. The temperature
ramp increment was 2.5°C/s for all steps. Plates were read
on a QX100 droplet reader with QuantaSoft v1.3.2.0 soft-
ware (both from Bio-Rad Laboratories) to assess the num-
ber of droplets positive for PIK3CA mutant (PIK3CAmu),
wild type (WT), both, or neither. At least two negative
control wells with no DNA were included in every run.
The concentration of PIK3CA mutant DNA (copies of
PIK3CAmu DNA per droplet) was estimated based on the
Poisson distribution using the number of PIK3CAmu
copies per droplet, MPIK3CAmu = −ln(1 − (nPIK3CAmu/N)),
where nPIK3CAmu is the number of droplets positive for the
PIK3CA 6-carboxyfluorescein (FAM) probe and N is the
total number of droplets. The DNA concentration in
the reaction was estimated as follows: MDNAconc = −ln(1 −
(nDNAconc/N)), where nDNAconc is the number of droplets
positive for PIK3CA FAM probe and PIK3CA VIC probe
(Life Technologies, Carlsbad, CA, USA) and N is the total
number of droplets. The fraction mutation is MPIK3CAmu/
MDNAconc.
Gene signatures
Multiple GSs have been developed to represent the PI3K
pathway, such as the PIK3CA-GS [6], PTEN-loss-GS [26]
and PI3K-GS [27]. We reproduced each signature by
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(Illumina, Inc, San Diego, CA, USA) and, where multiple
probes existed, taking the most variable of those probes.
The GS score for each sample was calculated by perform-
ing gene centring and then weighted averaging as previ-
ously described [6]:





where n is the number of genes in a module, Xi repre-
sents the normalised gene expression in the sample and
gene-specific weights Wi are equal to +1 or −1 according
to the direction of their association with the phenotype
in the original publication.
PIK3CA-GS (Loi), PTEN-loss-GS (Saal) and PI3K-
GS (Creighton) were also adapted by the removal of
proliferation-associated genes (PAGs) to generate three
new signatures (PIK3CA-noPAG-GS, PTEN-loss-noPAG-
GS and PI3K-noPAG-GS), because the presence of mul-
tiple PAGs dominate the GSs and could potentially mask
the PI3K pathway–related features of the GSs. These PAGs
were identified by three methods: genes functionally asso-
ciated with cell-cycle progression and cell division accord-
ing to Gene Ontology annotations [28], genes showing
cell-cycle stage–specific expression [28,29] and a tumour-
based ‘proliferation cluster’ [28,30-32]. The details of the
genes used from each GS are listed in Additional file 3:
Table S3.
Statistical analyses
All statistical analyses were performed in GraphPad
Prism 6.0 (GraphPad Software, La Jolla, CA, USA) and R
version 3.0.1 (R Foundation for Statistical Computing
[http://www.r-project.org/]) or in MS Excel (Microsoft,
Redmond, WA, USA). Associations between tumour size
(T2 or T3), nodal status (positive or negative for nodal
involvement), stage (2, 3 or 4), grade (1, 2 or 3), hist-
ology (ductal, lobular or other), HER2 positivity, intrinsic
subtypes (luminal A vs luminal B) and PIK3CA mutation
status were assessed using Fisher’s exact test. The associ-
ation between continuous variables, such as ER, PgR,
Ki67 and GS scores, with mutation status was evaluated
using the nonparametric Mann–Whitney U test or
Kruskal–Wallis test with Dunnett’s multiple comparison
test. For HS vs non-HS comparisons, if a sample con-
tained both types of mutation, it was excluded from the
analysis. Correlations between the GS scores and Ki67
IHC values were calculated using Spearman’s rank correl-
ation analysis. All P-values reported are two-sided, and
values <0.05 were considered statistically significant.
Cases with missing values were excluded. The number of
samples within each analysis can be found in the relevant
analysis and in Additional file 4: Table S4.Results
PIK3CA mutations in ER + breast cancer
DNA from tumours of 126 patients included in the 0223
trial was available, among which 19 samples were not
assessed because of a lack of sufficient material. We
processed 107 samples using the Sequenom system,
which provided us with complete mutational profiles for
85 samples to which the data reported here relate. The
demographics of the 85 patients are shown in Table 1.
At least one PIK3CA mutation was detected in 25 tu-
mours (29%). Of those 25, 23 had one mutation, 1 had 3
mutations (exon 7 E453K, exon 9 E542K and E545K)
and another had 2 mutations (exon 9 E545K and exon
20 H1047R). Of the 28 mutations, 20 (71%) were in HSs:
14% E542K (n = 4), 32% E545K (n = 9) and 25% H1047R
(n = 7) (Figure 1, Additional file 5: Table S5).
The presence of E542K, E545K and H1047L/R muta-
tions was also assessed by ddPCR in 25 samples with mu-
tations, including 19 samples that contained 1 of these
mutations, which were revealed by Sequenom analysis.
Nineteen of the twenty-one mutations were confirmed by
ddPCR. Of the two that were not confirmed, one was
below the threshold for sample calling (>25 VIC+ droplets)
by ddPCR because of low quantity of DNA and the other
was discordant. However, as a result of this excellent cor-
relation, the mutations detected with the Sequenom system
were carried forward for downstream analyses.
Relationship of PIK3CA mutations with clinicopathological
features
The presence of any mutation was associated with low-
grade tumours (P = 0.033), but not with size as charac-
terized by T category (T2 vs T3; P = 0.61) (Table 1).
Quantitative ER and PgR protein expression (assessed by
H-score) was available for 83 of 85 cases. In patients
with PIK3CA mutations, the median ER levels were sig-
nificantly higher: WT = 215.1 (n = 58, IQR = 173.7 to
230.9) and Mu = 230.5 (n = 25, IQR = 214.3 to 251.1)
(P = 0.017) (Figure 2A). Amongst the mutation cases,
median PgR H-scores were also significantly higher:
WT = 90.6 (n = 58, IQR = 2.25 to 205.3) and Mu = 213.8
(n = 25, QR = 109.4 to 275.6) (P = 0.006) (Figure 2B). All
except two of the mutation cases were PgR+. Despite
this, when PgR was dichotomised as positive or nega-
tive, no significant association with mutation status was
identified (Table 1).
ER H-score and PgR H-score were also analysed with
regard to HS and non-HS mutations. We found that
non-HS mutations exhibited significantly higher ER
and PgR expression compared to WT and HS samples.
For ER, the median expression data were as follows:
WT = 215.1 (n = 58, IQR = 173.7 to 230.9), HS = 220.4
(n = 17, IQR = 202.2 to 247.7), non-HS = 249.4 (n = 7,
IQR = 235.4 to 255.2), HS vs non-HS/WT = ns, WT vs
Table 1 Relationship between PIK3CA mutation status and standard clinicopathological parametersa
Number of patients (% in brackets)
Demographic characteristics Total population number (%) PIK3CA WT, n (%) PIK3CA mutation, n (%) P-valueb
Totals 85 (100) 60 (70.6) 25 (29.4)
Mean age (±SD), yr 70.9 (8.5) 71.0 (8.4) 70.7 (9.0)
Histological grade 0.033
Number available 70 47 23
1 13 (18.6) 5 (10.6) 8 (34.8)
2 43 (61.4) 30 (63.8) 13 (56.5)
3 14 (20.0) 12 (25.5) 2 (8.7)
Unknown 15
Stage (n = 85) 0.780
2 48 (56.5) 33 (55.0) 15 (60.0)
3 28 (32.9) 21 (35.0) 7 (28.0)
4 9 (10.6) 6 (10.0) 3 (12.0)
Lymph nodes (n = 85) 0.472
Positive 35 (41.2) 23 (38.3) 12 (48.0)
Negative 50 (58.8) 37 (61.7) 13 (52.0)
Tumour sizec (n = 76) 0.610
T2 48 (63.2) 33 (61.1) 15 (68.2)
T3 28 (36.8) 21 (38.9) 7 (31.2)
Histology 0.725
Number available 58 38 20
Ductal 44 (75.9) 29 (76.3) 15 (75)
Lobular 8 (13.8) 6 (15.8) 2 (10)
Other 6 (10.3) 3 (7.9) 3 (15)
Unknown 27
ERα status 1.000
Number available 83 25 58
Negative 0 0 0
Positive 83 (100) 25 (100) 58 (100)
Unknown 2
PgR status 0.49
Number available 83 58 25
Negative 11 (12.9) 9 (15.5) 2 (8)
Positive 72 (86.7) 49 (84.5) 23 (92)
Unknown 2
HER2 status 1.000
Number available 82 57 25
Negative 69 (84.1) 48 (84.2) 21 (84)
Positive 13 (15.9) 9 (15.8) 4 (16)
Unknown 3
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Table 1 Relationship between PIK3CA mutation status and standard clinicopathological parametersa (Continued)
Subtype 0.039
Number available 46 23 13
Luminal A 22 (47.8) 11 (47.8) 11 (84.6)
Luminal B 24 (52.2) 12 (52.2) 2 (15.4)
aER, Oestrogen receptor; HER2, Human epidermal growth factor receptor 2; PgR, Progesterone receptor; PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit α; WT, Wild type. bFisher’s exact test. P-value relates to the comparison between wild type and mutation. cMeasurements of tumour size were
taken by caliper (n = 45), magnetic resonance imaging (n = 2), physical examination (n = 25) or ultrasound (n = 4). T4 and T4a patients (n = 1 and n = 8, respectively)
were excluded from the analysis of tumour size.
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values were as follows: WT = 90.60 (n = 58, IQR =
2.25 to 205.3), HS = 168.0 (n = 17, IQR = 77.7 to
224.4) and non-HS = 258.3 (n = 7, IQR = 196.2 to
281.9), with a nonsignificant correlation between HS and
non-HS/WT and a significant difference between WT
and non-HS (P = 0.014). One sample contained both a
HS mutation and a non-HS mutation and was therefore
excluded from the analysis.
Regarding the relationship between HER2 status and
PIK3CA mutations, 69 cases were HER2− and harboured
21 mutations and 13 cases were HER2+ and contained 4
mutations (P = ns) (Table 1).
Intrinsic subtype status according to the PAM50 GS
[22] was available for 66 of 85 samples, among which we
classified 22 as luminal A, 14 as luminal B, 17 as normal,
3 as basal-like and 10 as HER2-enriched. There were 11
(50%) of 22 luminal A and 2 (14%) of 14 luminal B mu-
tation cases (P = 0.039) (Table 1). Thus, 11 (85%) of the
13 mutation cases were categorised as luminal A.
Signatures of phosphatidylinositol 3-kinase pathway
activity
Three GS scores were calculated for each sample at
baseline. The PIK3CA-GS (Loi) was derived from exon
20 mutations and has been shown to negatively correlate
with GSs of proliferation, AKT activation and PTEN loss
whilst positively correlating with ESR1 expression [6].
The PTEN-loss-GS (Saal) was developed to represent
IHC-detectable PTEN loss in BC [26]. Its association
with PIK3CA mutation status suggests that the signature
integrates various lesions in the PI3K pathway. The
PI3K-GS (Creighton) is based on the set of genes in which
expression was induced or repressed by PI3K inhibitorsFigure 1 Representation of the frequency of mutations identified in t
coloured red. The percentage for each type is the percentage of total mut[27]. As measurements of the same pathway, it might be
expected that the signatures would correlate with one an-
other. However, although the PI3K-GS (Creighton) and
PTEN-loss-GS (Saal) were strongly positively correlated
with one another (r = 0.657, P < 0.0001), the PIK3CA-GS
(Loi) and PI3K-GS (Creighton) showed a weak, non-
significant trend towards negative correlation (r = −0.218,
P = 0.079), and the PIK3CA-GS (Loi) and PTEN-loss-GS
(Saal) were minimally inversely correlated (r = −0.292,
P = 0.017). The PIK3CA-GS (Loi) has been reported to
correlate with ESR1 [6], but we did not see this relation-
ship (r = −0.122, P = 0.330). It did, however, show a slight
trend towards correlation with ER protein expression
(r = 0.240, P = 0.055).PIK3CA mutation status and gene signatures representing
the phosphatidylinositol 3-kinase pathway
The PIK3CA-GS (Loi) was strongly associated with mu-
tation status, with mutants having higher median GS
scores: WT = −0.051 (n = 50, IQR = −0.162 to 0.086) and
Mu = 0.140 (n = 16, IQR = 0.062 to 0.254) (P < 0.0001)
(Figure 3A). Because this signature was derived using
exon 20 mutations, we ran the same analysis excluding
the exon 20 mutations and found a significant relation-
ship with non–exon 20 mutations: WT = −0.051 (n = 50,
IQR = −0.162 to 0.086) and Mu = 0.143 (n = 11, IQR =
0.056 to 0.240) (P = 0.0003) (data not shown).
The PI3K-GS (Creighton) was not associated with
PIK3CA mutation status. Median values were WT= 0.009
(n = 50, IQR = −0.034 to 0.036) and Mu = −0.007 (n = 16,
IQR = −0.037 to 0.016) (P = 0.341) (Figure 3B). The PTEN-
loss-GS (Saal) was significantly inversely associated
with mutation status. Median values were WT = 0.025he PIK3CA gene. Mutations in the hotspot regions of the gene are
ations recorded.
Figure 2 Relationship of PIK3CA mutation status with biomarkers and molecular subtype. (A) Oestrogen receptor (ER) (n = 83).
(B) Progesterone receptor (PgR) (n = 83). Data are shown with medians and IQRs. Mu, Mutant; WT, Wild type.
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IQR = −0.137 to 0.029) (P = 0.041) (Figure 3C).
When we excluded PAGs from the GSs, the associ-
ation with mutation status was maintained for the
PIK3CA-GS (Loi) and the PI3K-GS (Creighton). For
PIK3CA-GS (Loi), the median values were WT = −0.041
(n = 50, IQR = −0.166 to 0.095) and Mu = 0.151 (n = 16,
IQR = 0.051 to 0.259) (P < 0.0001) (data not shown). For
PI3K-GS (Creighton), the median values were WT= 0.006
(n = 50, IQR = −0.031 to 0.039) and Mu = −0.002 (n = 16,
IQR = −0.035 to 0.021) (P = 0.372) (data not shown). How-
ever, the PTEN-loss-GS (Saal) association lost its statistical
significance. The median values for PTEN-loss-GS (Saal)
were WT= −0.002 (n = 50, IQR = −0.049 to 0.089) and
Mu = −0.007 (n = 16, IQR = −0.081 to 0.041) (P = 0.503)
(data not shown), indicating that this GS is influenced by
proliferation genes (27.8% of genes in the GS are PAGs,
compared to 12% for PIK3CA-GS and 15% for PI3K-GS).
Association of PIK3CA mutation status and gene
signatures with Ki67
There was a borderline significant difference (P = 0.051) in
baseline Ki67 between PIK3CA WTand mutation samples,Figure 3 Relationship between PIK3CA mutation status and genetic s
(Saal). Data are shown with medians and IQRs. GS, Gene signature; Mu, Muwith patients with the mutation having lower levels of pro-
liferation (Table 2). We also analysed baseline Ki67 with re-
gard to HS and non-HS mutations and found no evidence
for a distinction to be made (P = 0.144).
There was no significant correlation between baseline
Ki67 and the PIK3CA-GS (Loi); however, there was a sig-
nificant positive correlation with the PI3K-GS (Creighton)
and PTEN-loss-GS (Saal) (Table 3). Because the various
GSs include PAGs, the influence of these PAGs on the sig-
natures could be considered substantial because prolifera-
tion has been strongly associated with the predictive and
prognostic utility of gene modules [33]. Therefore, three
modified GSs (noPAG version) which had PAGs removed
were developed. In the absence of PAGs, the relationships
of baseline Ki67 with the GSs were sustained.
Ki67 values after 2 weeks of treatment have been found
to be associated with residual risk during endocrine treat-
ment [20]. We found a weak significant relationship of
mutation patients’ having lower levels of 2-week Ki67
(P = 0.050) (Table 2), but no association with any of
the GSs, with or without PAGs (Table 3).
Ki67 levels were suppressed by median values of
69% and 77% in patients with WT and mutation GSs,ignatures. (A) PIK3CA-GS (Loi). (B) PI3K-GS (Creighton). (C) PTEN-loss-GS
tant; WT, Wild type. n = 66.
Table 2 Relationship between Ki67 and PIK3CA mutation
statusa
WT/Mu
n WT, median (IQR) Mu, median (IQR) P-value
Baseline Ki67 81 18.2 (56, 12.7 to 27.3) 12.5 (25, 5.7 to 21.0) 0.051
2-week Ki67 75 5.8 (52, 1.8 to 19.8) 3.1 (23, 1.0 to 7.2) 0.050
2-wk/pre-Ki67% 73 31.3 (50, 14.5 to 70.8) 23.1 (23, 11.6 to 44.2) 0.346
aMu, Mutant; WT, Wild type.
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nificant (Table 2 and Additional file 6: Figure S1). Simi-
larly, when we divided the patients into good and poor
responders, using a cut-off value of 65%, we identified no
difference in the proportion of good and poor responders
in the WT and mutation groups (P = 0.095) (data not
shown). In addition, there was no significant correlation
between any of the three GSs and 2-week pre-Ki67%
measurements (Table 3). We identified a slight trend to-
wards significance for PIK3CA-noPAG-GS (r = 0.246,
P = 0.067) (Table 3 and Additional file 7: Figure S2).
There were ten HER2+ samples with mutation status
and 2-week/pre-Ki67% data; however, the small sample
size precluded any meaningful separate analysis of this
subgroup.
Validation of Ki67 findings with regard to mutation status
using a publicly available data set
We conducted an analysis of 310 baseline samples from
the study by Ellis et al. [9] for which they had PIK3CA
mutation data. In this much larger data set, we found a
significant but weak association with baseline Ki67 and
discovered that WT samples had higher Ki67 levels
than mutation samples, with the following median values:
WT = 18.6 (n = 180, IQR = 10.3 to 31.4) and Mu = 14.9
(n = 130, IQR = 7.3 to 26.7) (P = 0.043). This confirms
the trend we identified in our smaller cohort. Unlike
our data, there was no trend towards mutation sam-
ples’ having lower 2-week Ki67 values, with median
data as follows: WT = 3.3 (n = 66, IQR = 1.2 to 8.3) and
Mu = 3.4 (n = 40, IQR = 1.2 to 7.8) (P = 0.926). In our
analysis of Ellis et al.’s data using our methodology for
Ki67 change, we also did not identify a significant asso-
ciation, with the following median data: WT = 76% sup-
pression (n = 66, IQR = 46 to 92) and Mu = 72% (n = 40,
IQR = 10 to 87) (P = 0.334) [9].
Discussion
Both de novo and acquired resistance to endocrine therapy
is a major clinical problem in the treatment of ER + BC. In
recent years, there has been a concerted effort to develop
therapeutic agents targeting kinases within the PI3K path-
way. This has grown out of the knowledge that deregula-
tion of this pathway is associated with with increasedtumour growth and resistance to therapy [34]. Further-
more, in recent clinical studies, researchers have shown
that the combination of everolimus, a targeted mTORC1
inhibitor, with the steroidal aromatase inhibitor exemes-
tane provides greater benefit than exemestane alone in the
third-line setting, increasing median progression-free sur-
vival from 4.1 to 10.6 months [35]. These data have led to
a concerted effort to identify biomarkers of response to
PI3K inhibitors in an attempt to identify those patients
most likely to gain benefit from this therapy.
Surprisingly, in multiple studies of PIK3CA in BC, re-
searchers have shown PIK3CA to be a highly mutated
gene in the luminal subtype that is associated with good
clinicopathological markers. Despite this finding, its rela-
tionship with response to endocrine therapy remains un-
clear. In our present study, we aimed to evaluate the
relationship of PIK3CA mutations and GSs representing
PI3K pathway activation with key biological features of
BC and short-term aromatase inhibitor–induced sup-
pression of Ki67, a validated intermediate endpoint for
benefit from endocrine therapy [11,36]. To our know-
ledge, our present study is, to date, the largest single
study of an aromatase inhibitor given in the neoadjuvant
setting in which the relationship between response to
treatment, PIK3CA mutations and multiple GSs of PI3K
has been examined.
Our findings regarding the prevalence of PIK3CA muta-
tions and the associations with lower risk markers in ER +
BC confirm previously reported results [5,7,9,13,14,37],
thus providing further evidence that mutations in this gene
seem to play a role in the biology of luminal BC. To com-
plement the mutation data, and for a better overview of
the activation status of the PI3K pathway, we investigated a
set of previously published GSs. PIK3CA mutation status
was associated with both the PIK3CA-GS (Loi) and PTEN-
loss-GS (Saal) pathways; however, in each case, there was
substantial overlap in the GSs between WT and Mu popu-
lations, such that GS could not act as an accurate surrogate
for mutation status.
The opposing association of the two signatures repre-
senting high pathway activation, PI3K-GS (Creighton)
and PTEN-loss-GS (Saal), with mutation status requires
careful consideration of the degree to which they repre-
sent pathway activation and the population in which
they are derived. They are far from equivalent, appar-
ently reflecting different aberrations driving the signatures.
The PI3K-GS, derived in vitro, was based on repression or
induction as a result of treatment with PI3K inhibitors,
whereas the PTEN-loss-GS recapitulates IHC-detectable
loss and could be more appropriate for use in studies of
basal-like tumours, in which it is associated with high path-
way activity [37]. With this in mind, it should also be noted
that the GSs are indicative of relative pathway activation
rather than absolute.
Table 3 Relationship between Ki67 and phosphatidylinositol 3-kinase pathway gene signaturesa
With PAGs Without PAGs
PIK3CA-GS (Loi) PI3K-GS (Creighton) PTEN-loss-GS (Saal) PIK3CA-noPAG-GS (Loi) PI3K-noPAG-GS (Creighton) PTEN-loss-noPAG-GS (Saal)
n Spearman’s r P-value Spearman’s r P-value Spearman’s r P-value Spearman’s r P-value Spearman’s r P-value Spearman’s r P-value
Baseline Ki67 64 −0.101 0.427 0.371 0.003 0.508 <0.0001 −0.082 0.518 0.370 0.003 0.347 0.005
2-week Ki67 57 0.084 0.534 0.188 0.162 0.219 0.102 0.120 0.374 0.186 0.167 0.132 0.329
2-wk/pre-Ki67% 56 0.212 0.117 0.036 0.792 −0.004 0.976 0.246 0.068 0.033 0.811 −0.017 0.901
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prehensive, the pathway consists of multiple nodes that
could be subject to mutation (or to other aberrations,
such as gain or loss of function), such that an alteration
at one particular point might not have the same impact
as another in terms of altering pathway activity.
Expression of Ki67 at baseline has been found to be
associated with a good prognosis. In previous analyses
of smaller cohorts, researchers have found that baseline
Ki67 was not significantly different between WT and
mutation samples overall or grouped by domain [12,16].
In this study, however, we found a borderline trend for
lower levels of Ki67 in mutation samples overall. This
novel finding is confirmed by our analysis of a larger
sample cohort from a public data set [9]. The median
and IQR Ki67 data in both our data set and that of
Ellis et al. are extremely similar, suggesting that the
weak significance in our data set is most likely due to the
small sample size.
In two previous reports, researchers have described
the effect of PIK3CA mutation status and response to
treatment measured by Ki67 change in small patient
cohorts with different treatments [12,16]. They identified
no significant association of mutation with response. We
also found no relationship in our larger, homogeneously
treated cohort, and, by investigating Ki67% change in a
larger public sample set [9], we confirmed that this re-
sult was not a false-negative due to sample size. The lack
of a relationship between PIK3CA mutation status and
2-week/pre-Ki67% in all the data sets suggests that the
presence of a PIK3CA mutation has limited, if any, im-
pact on the likelihood of benefit from presurgical ana-
strozole treatment in patients with primary BC.
Interestingly, in a neoadjuvant trial of ER + postmeno-
pausal patients, researchers found that PIK3CA exon 9
mutations, compared with exon 20 mutations, were less
responsive to letrozole alone, but that these patients were
as sensitive as the overall population to everolimus and
letrozole [38]. However, the number of patients in that
study was small. A pooled analysis of all published studies
would allow greater exploration of the significance of the
mutational subgroups because of increased power. The
researchers in the recently reported BOLERO-2 and
TAMRAD translational studies of ER +metastatic BC pa-
tients [39,40] found that all patients derived benefit from
the addition of everolimus to exemestane or tamoxifen, re-
spectively, regardless of their PIK3CA genotype. However,
the relevance of PIK3CA mutation to advanced, heavily
pretreated disease may differ from primary disease. The
early emergence of PIK3CA mutations in BC, as well as
their high prevalence and their associations with high ER
expression and good prognosis, suggests their functional
importance in the disease, but it may be that other aberra-
tions offer predictive potential. For example, patients withindependent activation of mTOR via low levels of the
tumour suppressor LKB1, an mTOR inhibitor, exhibited
greater benefit from everolimus [39].
The strengths of this study are the comprehensive
documentation of the presence of both common and
rare PIK3CA mutations (>94% of all PIK3CA mutations
recorded in BC) and the use of multiple GSs of the PI3K
pathway to catalogue and compare aspects of the PI3K
pathway. The use of the presurgical setting allowed the
mutations to be linked to response to treatment by using
a validated biomarker, in contrast to most other studies
in which researchers have considered association with
prognosis. We also verified the most important novel
data, lower baseline Ki67 in mutation samples, in a
large, publicly available data set. The moderate sample
size of this study does mean, however, that the ability
to determine the importance of the rare mutations is
underpowered. The numerous borderline trends could
come into significance in a larger data set, as shown by
the analysis of the data from Ellis and colleagues.
Conclusions
The results of this presurgical study of 85 breast tumours
treated with 2 weeks of anastrozole confirm the high preva-
lence of PIK3CA mutations and their relationship with
markers of good clinical prognosis in ER + disease. The
correlation of mutations with GSs of the PI3K pathway sug-
gests that PIK3CA mutants exhibit lower mTORC1 signal-
ling and reduced PI3K activity, despite their oncogenic
nature in vitro. The data reported herein show that the
presence of a PIK3CA mutation does not seem to attenuate
the response to short-term treatment with anastrozole and
therefore is not a biomarker of response as measured by
Ki67, which is an important finding, given the high fre-
quency of PIK3CA mutations and the widespread use of
anastrozole treatment in postmenopausal women.Additional files
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